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INTRODUCTION 
 
              Endotracheal tube  was first introduced in mid 20th century .Till that 
time endotracheal tube was packed on the side of sub glottis by anesthetic swab 
for preventing gas leakage and ribbon guaze was tied on other end for removal 
of the tube at extubation. Endotracheal tube cuffs maintains the airway pressure 
during inspiration when the patient is on mechanical ventilation and prevents 
aspiration. Pressure generated by endotracheal tube cuffs usually transmitted to 
tracheal mucosa when elevated above 30 cmH2O causes ischemia of tracheal 
mucosal vessels which leads to ciliary loss, inflammation, ulceration, 
hemorrhage acutely, later on by tracheal stenosis and trachea esophageal fistula. 
The occurence of tracheal ischemia is directly  related to the cuff pressure and 
duration of exposure. 
 
            Nitrous oxide, routinely used anesthetic gas readily diffuses inside the 
cuff thereby increasing the cuff pressure. Hyperinflation of the cuff causes 
tracheal mucosal lesions leading to sore throat, coughing, hoarseness which 
results in discomfort after extubation. 
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          Tracheal intubation can cause airway changes, injury, and nerve damage. 
The most common complication that occurs after tracheal intubation is sore 
throat which is related to tracheal tube size and cuff design. Nerve damage 
caused by intubation is due to high intracuff pressure. 
 
       Apart from cuff pressure, techniques of endotracheal tube intubation plays 
an important role in airway trauma and postoperative sore throat. Rapidly 
adapting stretch receptors present over the tracheal mucosa is responsible for 
endotracheal tube induced cough. These receptors are highly sensitive to 
mechanical stimuli. Intubation with endotracheal tube and hyperinflation of the 
cuff causes coughing after extubation. Injection of lignocaine into endotracheal 
tube cuff causes its diffusion through the semipermeable membrane of cuff 
which anaesthetize the tracheal mucosa. This increases the airway tolerance 
during general anaesthesia, minimizes the hemodynamic changes and incidence 
of coughing after extubation. 
 
Sodium bicarbonate increases the un-ionized form of local anesthetics 
which causes increase in diffusion of it through the cuff thereby reducing the 
dosage of local anesthetics. 
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AIM OF THE STUDY 
 
PRIMARY AIM OF THE STUDY: 
               To compare the cuff pressure when inflated with air or alkalinized 
lignocaine during general anaesthesia. 
 
SECONDARY AIM OF THE STUDY: 
i. To evaluate the haemodynamic changes during the intraoperative  period   
ii.  To evaluate airway tolerance during extubation.  
iii. To evaluate the incidence of post-extubation tracheal morbidity in  the 
form of     
a. Sore  throat. 
b. Coughing. 
c. Hoarseness of voice. 
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HISTORY 
 
Friedrich Trendelendurg -1871-described small, low volume inflatable cuffed 
rubber tracheal tube inserted into tracheostomy tube. 
William McEwen -July 5, 1878-did oral intubation blindly for anaesthesia and 
airway obstruction.  
Chevalier Jackson-1913- was the first person to use direct laryngoscopy for 
intubation. 
Eisenmenger-1893- was the first person to describe about the tracheal tube with 
high volume inflatable cuff. In 1952-cuffed tracheal tubes were used during 
polio epidemic (before that non-cuffed was used) 
.Ivan.W.Magill & Edagar S.Rowbotham –first used endotracheal tube for 
Facio-maxillary surgery. 
Magill tubes-made of red mineralized rubber fits the airway. 
Arthur Guedel &Ralph .M.Waters-1928-promotes cuffed endotracheal tubes. 
Disposable plastic tubes replaces Red rubber tube for following reasons. 
1. cross infection & release of toxins. 
2. high pressure cuff causes tracheal erosion. 
3. rubber tubes deteriorates on repeated autoclaving 
Humphry Davy- was the first person to note the analgesic efficacy of nitrous 
oxide and he named it as “Laughing gas”.  
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Horace Wells-used Nitrous oxide for  tooth extraction. 
Joseph Priestley- 1772- a French chemist who first synthesized Nitrous oxide, 
called it as “phlogisticated nitrous air”. 
Gardner Q.Colton-promoted the continued use of  nitrous oxide. 
Edmund Andrews-described the idea of using N2O with oxygen. 
Nils Lofgren-1943-synthesised first amino amide ester Xylocaine  (Lignocaine) 
Bendt Lundquist was the first person who made experimental injection of 
lignocaine on himself  
In 1949-lignocaine was first marketed. 
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PHARMACOLOGY OF LIGNOCAINE 
 
Lignocaine is a synthetic amino amide derivative of local anesthetics with 
intermediate potency and duration. It is the standard local anesthetics to which 
all other agents are compared. It is the most commonly used local anesthetic. It 
can also be used as an antiarrhythmic. It can be given by all routes.(intravenous, 
intrathecal, infiltration, local applications like ointment, sprays, jelly etc.) 
 
MECHANISM OF ACTION: 
Lignocaine  after entering the cell membrane binds to the inner portion of 
the resting sodium channel receptor. It prevents the propagation of nerve 
impulse through the ion-selective sodium channel in the nerve membranes. This  
decreases  the depolarization rate, so that the threshold potential is not reached.  
Thereby, action potential  generation is inhibited, without altering the membrane  
potential. 
 
PHYSIOCHEMICAL PROPERTIES: 
Molecular weight               :  234 
Weak base with a pka            :  7.6 – 7.8 
Stable, not decomposed by heating, acids or alkalies 
Compared to bupivacaine, it is less lipid soluble 
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PHARMACOKINETICS: 
 
Absorption: 
 
 Lignocaine is absorbed into the blood stream from the site of application 
or injection. Blood flow to that area and use of epinephrine determines the rate 
of absorption. 
 
Metabolism and Excretion: 
 
              It is metabolized in liver by oxidative de-alkylation to mono ethyl 
glycinexylidide which on further hydrolysis produces xylidide. Hepatic blood 
flow determines its metabolism. 80% activity of the parent drug is by Mono 
ethylglycine xylidideand 10% of its activity by xylidide. 75% of xylidide is 
excreted in the urine as 4 – hydroxyl – 2,6 – dimethylaniline. 
 
Onset of action: 
The onset of action varies with the site of application of lignocaine. For 
topical anaesthesia its onset - 5-10 minutes, For conduction anaesthesia in small 
nerves- 5-10 minutes For large nerves - 10-15 minutes For Intravenous 
administration -1-2 minutes. 70% of the drug binds to α1 acid glycoproteins.  
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Volume of distribution 91 litres.  
Lignocaine has a  triphasic  distribution . 
Rapid distribution phase (α): during this phase, the drug is distributed 
to highly vascular regions with t ½ α of 1 minute. 
Slow disappearance phase (β): here the drug is distributed to slowly 
equilibrating tissues with t ½ β of 9.6min. 
Finally the drug goes to slow transformation and  
Excretion phase ( δ ) :Where the t½ δ is 1.6 hrs.  
 
Clearance - 0.95 litres per minute. 
 
 
Availability: 
 
• 2% lignocaine ointment, 5% lignocaine ointment 
• 10% lignocaine spray 
• 2% lignocaine Jelly 
• 4% lignocaine aqueous solution 
• 4% lignocaine viscous 
• 4% lignocaine with adrenaline as 1 in 200000 dilution – 30 ml vial. 
• 2% lignocaine with adrenaline as 1 in 200000 dilution  
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• 2% lignocaine – plain – 30 ml vial –contains methyl and propyl paraben 
as        preservative 
• 2% lignocaine (xylocard) without preservative – 50 ml vial for 
intravenous   use 
• 5% heavy 2 ml ampoules which contain 50 mg of lignocaine / ml with 75  
mg – 100 mg of dextrose 
 
PHARMACODYNAMICS: 
 
Local actions: 
 
It acts locally causing loss of pain, touch and temperature sensation. 
Motor power and vasomotor tone is also lost in the region supplied by the 
nerves blocked. 
 
SYSTEMIC ACTIONS: 
 
Its action depends on the site / route (intravenous) of administration. 
 
 
 
 10 
 
Cardiovascular system: 
It stabilizes the myocardial cell membrane. It depresses myocardial 
automaticity by inhibiting the action potential and reducing the duration of 
effective refractory period. At higher concentration, cardiac conductivity and 
contractility are depressed. All these effects result from direct cardiac muscle 
membrane changes occurring due to cardiac sodium channel blockade. It 
suppresses ectopic foci by stabilizing the membrane of damaged and excitable 
cells.  
Vascular smooth muscle : 
It acts on vascular smooth muscle producing vasodilatation. 
 
Respiratory system : 
Lignocaine depresses the ventilatory response to low PaO2 (hypoxic 
drive).Direct exposure of local anaesthetic to higher centres like medulla or 
peripheral nerves (intercostal ,phrenic nerve) causes respiratory depression. -
Since it relaxes bronchial smooth muscle, Intravenous lignocaine may be 
effective in blocking the reflex bronchoconstriction associated with intubation. 
 
Central nervous system : 
Lignocaine causes a sequence of stimulation followed by depression. It 
causes sedation on intravenous administration. Intravenous administration 
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decreases cerebral blood flow and attenuates the rise in intracranial pressure that 
accompanies intubation. Lignocaine injection is capable of reducing the 
Minimal Alveolar Concentration of volatile anaesthetics by 40%. 
Musculoskeletal:  
Lignocaine causes lytic degeneration, edema and necrosis of muscle 
fibres. 
Hematological :  
 It enhances fibrinolysis thereby increasing the clotting time. 
 
Indications: 
 
For infiltration block, peripheral nerve blocks, topical anaesthesia, 
intravenous regional anaesthesia, intra cuff injection (with sodium bicarbonate), 
spinal and epidural anaesthesia 
1. Antiarrhythmic: 
Lignocaine is a class IB anti arrhythmic drug. It is used in the treatment of 
• Ventricular tacharrhythmias 
• Arrhythmias due to acute myocardial Infarction during cardiac surgery 
• Digitalis toxicity – since it does not worsen AtrioVentricular– block 
2. It is used to prevent increases in intracranial pressure during intubation –  
          antitussive effect may be the reason for this action. 
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3. It suppresses noxious reflexes (coughing) & sympathetic stimulations 
associated with endotracheal suctioning and intubation. 
     4. It is used intravenously as an analgesic for chronic pain states 
     5. It is used as a supplement to general anaetheisa. 
 
Contraindications: 
1. It should not be used in patients with (hypersensitivity) allergic disorder. 
2. It should not be used along with vasoconstrictor in digits of hand, feet and 
penis. 
3. It is contraindicated in patients with Stokes Adams syndrome, severe degree 
of heart block 
 
Doses: 
Maximum recommended dose : 
Plain-3mg / kg 
plain with adrenaline-7 mg / kg 
plain without preservative for reflex suppression -1.5 mg / kg iv. 
 
Drug interactions: 
β Blockers: Co administration of beta blockers, increases the toxicity by 
increasing the serum levels of lignocaine by reducing lignocaine’s metabolism. 
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Anticonvulsant agents: It increases the metabolism of lignocaine. 
Non depolarizing muscle relaxants: lignocaine potentiates the blockade 
of non- depolarizing muscle relaxant. 
Opioids and α 2 adrenergic agonists: These  drugs increases the 
analgesic action of lignocaine. 
Anti-arrhythmic agents: anti arrhythmic effect of lignocaine is 
increased by these agents. 
 
Toxicity: 
Lignocaine toxicity is due to systemic absorption of locally administered 
lignocaine or due to accidental intravenous administration of large doses of 
lignocaine. The central nervous system is most commonly affected. 
 
Symptoms and blood levels: 
Light headedness, tinnitus, circumoral and tongue 
numbness(anticonvulsant and antiarrhythmic activity): 4 micrograms / ml 
visual disturbances: 6 micrograms / ml 
muscular twitching: 8 micrograms / ml 
convulsions : 10 micrograms / ml 
unconsciousness : 12 micrograms / ml 
coma: 15 micrograms / ml 
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respiratory arrest: 20 micrograms / ml 
cardiovascular collapse: 26 micrograms / ml 
 
Treatment of toxicity: 
Lignocaine toxicity can be identified earlier by continuous monitoring of 
Cardiovascular and Respiratory status. 
• Barbiturates or benzodiazepines are used to treat convulsion. 
• Succinylcholine 1mg/kg used to paralyze and to intubate the patient to have 
airway control during seizures. 
• Ventricular fibrillation can be treated by defibrillation. 
• 100 % oxygenation, intubation and ventilation. 
• Maintain Blood Pressure by rapid infusion of Intra Venous fluids, use of  
  vasopressors and put the patient in Trendelenberg’s position. 
• Treat electrolyte imbalance. 
 
Adverse effects: 
1.Allergic and hypersensitivity reactions :  
Methyl paraben used as a preservative causes allergic and hypersensitivity  
reactions.  
 2.Cardiovascular system : hypotension, bradycardia. 
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PHARMACOLOGY OF NITROUS OXIDE 
 
Molecular Formula      :  N2O 
Molecular Weight        :  44gm/mol 
Appearance             : colour less gas 
Density                   :  1.97 gm/L 
Melting point            :  -90.86degree celcius 
Boiling point            :  -88.48 degree celcius 
Vapour pressure          :  5150 KPa 
Critical temperature     :  36.5 degree celcius 
Minimum alveolar concentration: 104 
 
SYNTHESIS: 
Nitrous Oxide is synthesized by heating ammonium nitrate by thermal 
decomposition. 
 
BIOTRANSFORMATION: 
It is mostly excreted through lungs, small amount through skin, <0.01% 
undergoes reductive metabolism in GIT by anaerobic bacteria. 
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Effects on organ system: 
Cardiovascular system: 
  It causes direct myocardial depressant effect. It increases the 
catecholamine release and thereby increases the Blood Pressure, Pulse Rate, 
Cardiac output (indirectly).Nitrous oxide increases the incidence of epinephrine 
induced arrhythmias. It increases the pulmonary vascular resistance by 
constriction of pulmonary smooth muscle thereby increases the right ventricular 
end-diastolic pressure. 
 
Respiratory System: 
   It increases the respiratory rate, but decreases the tidal volume.  It 
depresses the hypoxic drive mediated by peripheral chemoreceptor (carotid 
bodies). 
 
Central nervous system: 
   It increases the cerebral blood flow, cerebral metabolic oxygen demand 
(CMRO2),and also causes mild increase in intracranial pressure.Renal system: 
   It decreases the renal blood flow by increasing the renal vascular 
resistance, thereby decreases the GFR, urine output. 
Hepatic system:    
 It decreases the hepatic blood flow. 
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Gastrointestinal system: 
   It activates the vomiting &chemoreceptor trigger zone in medulla and 
causes nausea &vomiting. 
 
Neuromuscular system: 
    It Does not provide good muscle relaxation. It doesn’t trigger malignant 
hyperthermia. 
 
ADVERSE EFFECTS: 
        It diffuses through the air filled cavities thereby increases the intra cuff 
pressure which results in sore throat after extubation. 
      It inhibits methionine synthetase necessary for myelin formation & 
thymidylate synthetase necessary for DNA synthesis 
  On prolonged exposure causes megaloblastic anemia, pernicious  
anemia, and peripheral neuropathy. 
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TRACHEAL ANATOMY 
 
The trachea is a membranocartilaginous tube. It extends from sixth 
cervical vertebra to the fifth thoracic vertebra. It bifurcates at lower border of  
fourth thoracic vertebra into two bronchi, the right  and the left. The right 
bronchus is shorter, wider and in line with trachea ,whereas the left bronchus is 
longer and narrower. Compared to adult, children have shorter and mobile 
trachea which is more deeply placed posteriorly. It measures about 11 cm. in 
length; its diameter, from side to side, is from 2 to 2.5 cm., being always greater 
in the male than in the female. During inspiration, bifurcation gets lowered at 
C6 but during expiration it moves about one vertebral level. Trachea is kept 
patent by U-shaped ring of elastic cartilage embedded in its wall. Trachealis  
muscle which is made of smooth muscle fibres connects the posterior free ends 
of the cartilaginous ring. 
Relations:  
Anteriorly: sternum, thymus gland, arch of aorta, common carotid & 
Brachio-cephalic arteries, left brachiocephalic vein. 
Posteriorly: oesophagus, left recurrent laryngeal nerve. 
Right side: azygous vein, right vagus nerve, pleura. 
Left side: arch of aorta, left common carotid artery, left subclavian artery, 
left Brachio-cephalic artery, left vagus nerve, left phrenic nerve, pleura 
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Blood supply: 
Upper two third of the trachea is supplied by inferior thyroid artery and 
Lower one third of the trachea by bronchial artery 
 
Nerve Supply: 
Vagus and recurrent laryngeal nerve supplies the sensory innervation to 
the trachea .Trachealis muscle is supplied by sympathetic nerves. 
 
Lymphatic Drainage: 
  Pretracheal, paratracheal, & deep cervical lymph nodes provides 
lymphatic drainage for the trachea. 
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TRACHEAL HISTOLOGY 
 
  Tracheal mucosal epithelium-psuedostratified ciliated columnar 
epithelium (with numerous globlet cells) with thick basement membrane. 
 Lamina propria-loose connective tissue layer forms the mucosal layer 
along with epithelial layer. 
 Submucosal layer-made of longitudinal elastic fibres with 
serosanguinous glands.Outside this connective tissue layer is made of hyaline 
cartilage which prevents tracheal lumen from collapsing.  
Muscularis propria-made of horizontally arranged muscle fibres that 
bridge the  cartilage. It acts to adjust the tracheal diameter. Adventitial layer-
outer most layer, made of connective tissue. 
 
 
 
 
 
 
 
 
 
TRACHEAL HISTOLOGY: 
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TRACHEAL INTUBATION 
      Tracheal intubation –Introducing a flexible plastic tube into the trachea to 
keep airway patent and thereby facilitating  mechanical ventilation and to 
prevent the occurrence of airway obstruction. The orotracheal intubation is the 
most common route of endotracheal intubation. Nasotracheal  intubation can 
also be done. It is the invasive method in which general anaesthesia with 
neuromuscular blocking agents are used for intubation.  
Intubation is facilitated by means of conventional laryngoscope, 
fibreoptic bronchoscope, video laryngoscope etc.to visualize the glottis. After 
intubation pilot balloon with cuff is inflated to keep endotracheal tube in place 
to prevent leakage of gases from the trachea and aspiration of gastric contents to 
the trachea.  
 
INDICATIONS: 
          1.Unconcious patient. 
          2. Airway obstruction. 
          3. Hypoxaemia. 
          4. Diagnostic &Therapeutic manipulation of airway. 
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METHODS TO CONFIRM ENDOTRACHEAL INTUBATION: 
       Endotracheal intubation is confirmed by following ways:  
1.Bilateral equal movement of the chest during ventilation. Bilateral equal air 
entry heard with help of stethoscope. Water vapour present over the lumen of 
the tube during expiration without gastric contents. 
2. Direct visualization of passage of tube by means of laryngoscope             
3. Capnography is also used to confirm the endotracheal tube position   
4.  Distal tip should be 2cm above the carina confirmed by chest X-ray. 
5. Calorimetric endtidal CO2 detector, self inflating esophageal bulb, an 
esophageal detecting device etc are used to confirm endotracheal 
intubation. 
 
COMPLICATIONS: 
   1.Sorethroat 
   2.Injury to airway (trauma to lips,gums etc) 
   3.Loosening,dislodgement of teeth  
   4.Arrhythmias,high blood pressure 
   5.Increased intracranial pressure, and intraocular pressure 
   6.Esophageal intubation 
   7.Laryngospasm,bronchospasm 
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CUFF SYSTEM, DESIGN & MATERIAL 
 
Requirements for the proper design of endotracheal tube cuffs specified by  
The American Society of Testing And Materials (ASTM) 
1.Maximum distance from the tip of the tube to the patient end varies with tube 
size 
2. Edge of cuff should not encircle the murphy eye. 
3.Cuff should inflates symmetrically without herniation over tube tip. 
 
CUFF SYSTEM: 
                        It includes 
                                   1. Cuff  
                                   2. An inflation system which consists of  
                                         a. An inflation tube 
                                         b. A pilot balloon 
                                         c. An inflation valve 
Main advantages of cuff are 
• It centers the tube in trachea 
• It prevents gas leakage along the tube during positive  
pressure ventilation. 
• It prevents the entry of upper airway contents into 
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trachea by providing a seal between the tube and 
tracheal wall 
 
MATERIALS: 
Characteristics of ideal tracheal tube materials are as follows: 
 It should be transparent 
 It should be inexpensive 
 It should be non-toxic 
 It should have long term usage with frequent sterilization. 
 It should not be inflammable 
 It should be free of latex. 
 Both inner & outer surfaces of the tube should be dry and   
smooth for introducing suction catheter  etc. and to prevent  
    trauma to airway. 
 It should be non- kinkable 
 Even tube made of thin wall should be of sufficient strength. 
 It should not react with lubricants &anesthetic agents. 
 It should be thermolabile according to patients body temperature. 
          No substance will meet all these characteristics. 
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TYPES OF ENDOTRACHEAL TUBE BASED ON MATERIAL: 
                 1. Red rubber tube 
                  2. Poly vinyl chloride (PVC) tube 
                  3. Silicon tube 
 
Red rubber tube: 
                 It is still in use. It can be sterilized and used multiple times. 
Disadvantages: Lack of transparency, latex allergy, easily plugged by secretions 
are the disadvantages of red rubber tube. 
 
Polyvinyl chloride (PVC) tube:  
• Most widely used now-a-days for oral/ nasal intubation. 
• Disposable, low cost, resistant to kinking. 
• Radio-opaque marker along the tube. 
• Thermoplastic –get stiffen/soften according to body  
temperature. 
• Transparent –allows for observing movement of moisture  
during respiration & substance in the lumen. 
• Smooth surface allows easy passage of suction catheter 
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Silicon tube: 
 Rarely used 
 Reusable after sterilization. 
 Expensive 
 
TUBE DESIGN: 
 Outer and inner wall of the tube is circular so that less prone for kinking 
 Proximal machine end  can be shortened and distal end is  
bevel shape which faces left. 
 Murphy eye opposite the bevel edge function as the path for  
gas flow when there is an obstruction in bevel end. 
 Radio opaque line situated along whole length of the tube to  
confirm the tube position after intubation. 
 
SIZE OF THE ENDOTRACHEAL TUBE (Internal diameter) 
Male: 8 mm  , Female: 7.5mm 
New born upto 3 months: 3mm 
  3-9 months: 3.5mm 
  9-18 months: 4mm 
  2-6 years: AGE/3+ 3.5mm 
 >6 years: AGE/4+4.5mm 
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DEPTH OF ENDOTRACHEAL TUBE INSERTION: 
ADULT :     MALE: 23cms    FEMALE: 21cms 
CHILDREN: 
Orotracheal intubation: AGE/2 +12cms 
Nasotracheal intubation: AGE/2 +15cms 
 
CUFF TYPES : 
Low volume,  high pressure cuff  
High volume,  low pressure cuff.    
Low volume, High pressure cuff: 
       It has short diameter with small residual volume requires high  
       pressure to seal with trachea. 
Advantages: 
      It is most commonly used in adults, inexpensive, can be reused. 
      It has less incidence of sore throat and good protection against 
      aspiration. 
      It does not obscure the view during intubation. 
Disadvantages:      
       High pressure cuff are more prone to tracheal ischemic injury after  
       prolonged usage. Therefore for prolonged procedure /elective ventilation it  
       is better to use low pressure cuff. 
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High volume, low pressure cuff: 
    It has large diameter with large residual volume provides better sealing  
    without tracheal stretching. 
      Advantages: 
    It provides intracuff pressure similar to pressure on the tracheal wall.It  
    can be used for prolonged intubation. 
      Disadvantages: 
1. There is a greater incidence of sore throat associated with low 
pressure cuff.  
2. These tubes disturb the tube tip view, get torn easily and more prone 
for tube dislodgement. 
3. Use of N2O diffuses into the cuff will increase the pressure over 
tracheal mucosa. 
 
 
 
 
 
 
 
 
 
SCHEMATIC REPRESENTATION OF LOW VOLUME HIGH 
PRESSURE &HIGH VOLUME LOW PRESSURE CUFF 
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EFFECT OF NITROUS OXIDE ON CUFF PRESSURE 
During administration of Nitrous Oxide, there is an increase in cuff 
pressure and volume when inflated with air. Increase in cuff pressure is directly 
related to  
1. Nitrous Oxide partial pressure. 
2. Endotracheal tube cuff wall permeability.  
3. Duration of anaesthesia. 
The most of the disposable tubes were made of polyvinyl chloride. These 
cuffs will reach recommended cuff pressure limits when exposed to nitrous 
oxide anaesthesia for a period of time. Tubes made of silicon & polyvinyl 
chloride are more susceptible to nitrous oxide diffusion. Endotracheal tube cuffs 
with thin wall is also responsible for early diffusion of nitrous oxide so that 
critical cuff pressure will reach within 60 mins.  
 
MECHANISM OF NITROUS OXIDE DIFFUSION: 
The walls of the closed gas (air) filled compartments are more compliant. 
Nitrogen present in the air filled cavities has low blood solubility with blood: 
gas  partition coefficient of 0.015.Nitrous oxide can easily transfer across the 
membrane barrier in contrast to nitrogen so that nitrogen gets trapped inside the 
air filled cavities (Nitrogen is 35times less blood soluble when compared to 
nitrous oxide). During Nitrous oxide anaesthesia, there is a doubling of volume 
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of the cuff which depends on alveolar nitrous oxide concentration.  
Higher the alveolar  nitrous oxide concentration can cause increase in 
compartment volume.   
   Discontinuation of nitrous oxide decrease the pressure in the cuff. 
Increase in cuff pressure occur during high altitude, alteration in head position, 
Oxygen diffusion, head and neck surgeries, coughing, muscle tone changes. 
Cuff pressure decreases during hypothermic bypass. 
 
TABLE:1 ideal intra- cuff pressure for adults using PVC tubes. 
PRESSURE cm water mm Hg 
Ideal 20-30 15-22 
High >40 30 
Low <20 15 
 
Tracheal mucosal injury  related to lateral wall pressure and the duration 
of contact of tube with tracheal mucosa.Tracheal capillary pressure shouldnot 
exceed 30 cm of water or 15mm of Hg. 
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CUFF PRESSURE MONITOR 
1. Aneroid manometer –It is most commonly used cuff pressure monitor. It is 
precise and accurate but requires calibration, expensive and carries risk of 
infection. Pressure limiting valves act as a resorvior thereby keep the intra 
cuff pressure in the preset range. 
2. Lanz pressure-regulating valve: This monitor maintains the Cuff pressure 
around 30cm of water. It cannot be used in children.  In case of high airway 
pressure it does not form good seal. 
3. Brandt tube system: It can be used intra operatively during general     
anaesthesia. While using Nitrous Oxide anaesthesia, intra cuff pressure is 
stabilised by a large pilot cuff reservoir and an internal pressure regulating 
valve. 
4. Pressure easy cuff controller: This type of cuff pressure monitor is  
expensive. It should be set according to peak  inspiratory pressure. It is  
 an electronically operated device. 
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POST OPERATIVE SORE THROAT 
 
Incidence varies from 30-50 % 
 
ETIOLOGY: 
1. Tracheal mucosal injury due to intubation and instrumentation. 
2. Ischemia of mucosa due to reduced blood flow as a result of increased 
intracuff pressure. 
3. Erosion of mucosa due to irritation of airway (intubation etc.,) 
4. Drying of mucosa due to inhalational anesthetics. 
All the above factors lead to inflammation of airway. 
 
RISK FACTORS: 
1. Female sex. 
2. Duration of anesthesia. 
3. Position during surgery. 
4. Nasogastric tube usage. 
5. Suctioning of oropharynx. 
6. Agents like succinyl choline and anesthetic sprays 
7. Increased intracuff pressure. 
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EFFECT OF NITROUS OXIDE ON CUFF PRESSURE 
During administration of Nitrous Oxide, there is an increase in cuff 
pressure and volume when inflated with air. Increase in cuff pressure is directly 
related to  
1. Nitrous Oxide partial pressure. 
2. Endotracheal tube cuff wall permeability.  
3. Duration of anaesthesia. 
The most of the disposable tubes were made of polyvinyl chloride. These 
cuffs will reach recommended cuff pressure limits when exposed to nitrous 
oxide anaesthesia for a period of time. Tubes made of silicon & polyvinyl 
chloride are more susceptible to nitrous oxide diffusion. Endotracheal tube cuffs 
with thin wall is also responsible for early diffusion of nitrous oxide so that 
critical cuff pressure will reach within 60 mins.  
 
MECHANISM OF NITROUS OXIDE DIFFUSION: 
The walls of the closed gas (air) filled compartments are more compliant. 
Nitrogen present in the air filled cavities has low blood solubility with blood: 
gas  partition coefficient of 0.015.Nitrous oxide can easily transfer across the 
membrane barrier in contrast to nitrogen so that nitrogen gets trapped inside the 
air filled cavities (Nitrogen is 35times less blood soluble when compared to 
nitrous oxide). During Nitrous oxide anaesthesia, there is a doubling of volume 
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FACTORS AFFECTING POSTOPERATIVE SORETHROAT: 
1.Size of the Endo tracheal tube. 
2.Technique of insertion of Endotracheal tube. 
3.Lubricant application. 
4.Pressure inside the cuff. 
5.Nitrous oxide use during general anaesthesia. 
 
TREATMENT: 
1. Steroids and Non Steroidal anti-inflammatory agents 
2. Benzylamine hydrochloride. 
3. Alkalinized Lidocaine. 
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REVIEW OF LITERATURE 
 
1) Comparative Study between Intracuff buffered lignocaine and saline or 
air in patients undergoing ophthalmic surgeries with chronic airway 
disease. 
V.Jegadeesh ,V.V.Jayachandran, I.M.Banulakshmi,  
Department of anesthesiology, Sankara Nethralaya Vision research 
Foundation, Chennai, Tamil Nadu.  
 
V.V.Jayachandran et al (2009) studied that intra cuff injection of 
buffered lignocaine produces smooth extubation as cough receptors are 
blocked by more diffusion of basic form of local anesthetics across the PVC 
wall of the cuff.75 patients with history of chronic smoking &recently 
treated upper respiratory infection were randomized into 3 groups(25 in 
each group).Group A(air),Group B (saline6ml),Group C(6ml of 2% 
lignocaine+0.5ml 7.5%sodiumbicarbonate).They found out that extubation 
was smooth with buffered lignocaine group compared to Air Group & saline 
group. Sore throat incidence was higher in Air group compared to others. 
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2) The effect of intra cuff alkalinized 2% lignocaine on emergence 
coughing, sorethroat, hoarseness in smokers. 
 
Laís Helena Camacho Navarro; Rodrigo Moreira e Lima, Anesthesiologists  
 
Navvro et al (2012), conducted a randomized double blinded study in 
which he compared two Groups .50 patients undergoing general anesthesia 
using nitrous oxide with controlled ventilation were included in the study 
(n=25). Group L received 2%lidocaine with 8.4% sodium bicarbonate or 
Group S received 0.9% saline. The cuff was inflated to achieves pressure 
that prevents air leakage during positive pressure ventilation. He concluded 
that Group L superior to Group S in preventing sorethroat and cough. 
 
3) Comparative Study between Alkalinized intra cuff lignocaine & gel 
lubrication – in prevention of emergence phenomena after 
Endotracheal intubation. 
J.P.Estebe, Service d’ Anaesthesisa reanimation chirurgicale. British journal 
of anestheisia 2004 
 
A study was conducted on diffusion of buffered lignocaine solution using  
high-volume and low pressure ETT cuff. They also have done a  study in 40 
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patients , 20 in each group- Group G  received buffered lignocaine-filled 
Endotracheal tube cuff with gel lubrication , Group W received buffered 
lidocaine-inflated cuff with  water lubrication ,Group C  gets an air-inflated 
cuff with Endotracheal tube lubrication with water .  Gel lubrication group 
reduces the incidence of sore throat after 24 hrs of extubation compared to 
other groups 
           Cough and restlessness before tracheal extubation were decreased in 
patients with the alkalinized lignocaine-filled cuffs compared with the air-
filled cuffs. After extubation, nausea, vomiting, dysphonia and hoarseness 
were greater for patients with air-filled cuffs compared with the lignocaine-
filled cuffs. No significant difference between the groups were recorded in 
arterial blood pressure and heart rate. In vitro data suggests that lower the 
NaHCO3 injection volume, the greater the release of lignocaine across a 
low-pressure, high-volume cuff endotracheal tube. 
 
4) Efficacy of cuff inflation media to prevent post intubation-related 
emergence phenomenon: air, saline and alkalinized lignocaine. 
European journals of anesthesia 2002 
Shroff et al conducted  a study among  150 patients undergoing surgery 
under GA with Controlled ventilation. Patients were divided into 3 equal  
groups  of air,  saline and alkalinized lignocaine as inflating agent. The 
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amount of inflating agent used, pressure inside the cuff, duration of surgery, 
amount of  inflating agent withdrawn from the cuff and complications such 
as tube intolerance, coughing and bucking on the tube, hoarseness, 
restlessness, sore throat, breathlessness and laryngospasm were recorded. 
After intubation , the  pressure inside the cuff was higher in the air group at 
five mins, thirty mins, one  hour and just before extubation. Air volume was  
increased in air group  just before extubation  compared with a decrease in 
volume in the other groups. Lignocaine group had decreased tube 
intolerance, hoarseness and sore throat  
 
5)  The  incidence and severity  of postoperative sore throat  after the use 
of Air,  lignocaine, Saline  for inflating endotracheal tube cuff.  
Porter NE, Sidou V 
 
Variables which were standardized are endotracheal tube cuff design , 
size of endotracheal tube, technique of intubation ,laryngoscope blade, 
airway placement, suctioning, anesthetic technique. ASA status I, II, or III, 
female, adult patients who underwent gynecological procedures under 
general anesthesia were included. VAS score and  McGill Pain 
Questionnaire were administered to the Seventy five patients at 2 intervals 
between 1 to 3 hours &  22 to 25 hours postoperatively, for assessment of  
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postoperative sore throat. Kruskal-Wallis test  was used for analysis and it  
suggested that the  postoperative sore throat incidence was statistically 
insignificant among the 3 groups. 
 
6) The study of various application of lignocaine in prevention of 
postoperative Tracheal morbidity. 
Journal of clinical anesthesia 2002 
 
Soltani et al conducted a study in  204 American Society Of 
Anesthesiologists I and II patients posted for ophthalmic surgeries with 
general anesthesia. Patients were allocated into 6 groups  
G 1- Lignocaine spray (10%) over ETT 
G 2- Lignocaine spray (10%) over oropharynx 
G 3- ETT lubricated with 2% Lignocaine jelly. 
G 4- Intravenous Lignocaine. 
G 5-  Intracuff Lignocaine 
G 6 – ETT lubricated with Normal Saline. 
From the study he concluded that there was a decrease in incidence of 
cough in I.V and Intra cuff Lignocaine Group. There was an increased in 
incidence of sorethroat with ETT lubricated with Lignocaine jelly, saline, 
10% lignocaine spray compared to i.v and intracuff  Lignocaine. 
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7)  Effect of Intra cuff Lignocaine on Coughing during Emergence and  
Postoperative Sore Throat 
Sagheer as, mazhar iqbal, khawar ali. 
 
Sagheer et al studied in 100 patients regarding cough during and after 
extubation and postoperative sore throat at one and 24 hour after anesthesia. 
The endotracheal tube cuff was filled with 4 % lignocaine in one group and 
with air in the other group. There was significantly less frequency of cough 
in the lignocaine group. The incidence of postoperative sore throat was also 
decreased at first and twenty four hour after anesthesia. Using lignocaine to 
inflate the endotracheal cuff decreases the frequency of cough at extubation 
and postoperative sore throat. 
 
8) The Efficacy  of the Intra cuff buffered  Lignocaine  in general 
anaesthesiaUsingNitrousOxide. 
Shin JC, Kim KS, Kim YJ, Choi WJ, Koo MS. Korean journal of 
anesthesiology 2008. 
 
           Shin et al done a study  in   patients undergoing thyroid surgeries .These 
patients were divided into four  groups-30 each 
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Group A alkalinized lignocaine (2ml) 
Group B  alkalinized lignocaine (4 ml) 
Group C air (6ml) 
Group L plain lignocaine 
Significant decrease in incidence of postoperative sore throat after 24 hrs 
in alkalinized  lignocaine group  in comparative to air or lignocaine group but 
both alkalinized group was statistically insignificant. ETT tolerance was good 
with alkalinized lignocaine group .Cough during extubation ,voice change 
after extubation was less in alkalinized lignocaine group compared to other 
two. From the study he concluded that  buffered lignocaine is considered as 
better adjuvant to intracuff air using nitrous oxide anesthesia. 
 
9)  Comparing three different lignocaine regimens  to inflate endotracheal 
tube cuff in preventing coughing during recovery from general 
anesthesia Huang .C.J 
Journal -  acta anesthesiology 1998. 
 
80  ASA Class I-II patients  who  underwent  elective surgeries were  
randomly assigned into 4  groups.   Endotracheal tube cuff was inflated  
with one of  following solution: normal saline 6 ml (Group A), 4% 
lignocaine 6 ml at room temperature (Group B), 4%lignocaine 5 ml + 7% 
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sodium bicarbonate 1 ml at room temperature (Group C), and 4% lignocaine 
5 ml + 7% sodium bicarbonate 1 ml warmed to 38 degrees C (Group D). 
Changes of vital signs as well as the times of coughing in the course of 
extubation and post-extubation complications were recorded. Statistically 
significant difference in coughing was noted in experimental groups 
(B,C,D)when compared to Group A. Sore throat incidence  was higher  in 
Group A. Hemodynamic changes were higher in experimental groups (B,C) 
before extubation. Finally Huang et al concluded that alkalinized and 
warmed lignocaine prestored in endotracheal tube cuff can greatly reduce 
ETT induced coughing and provide smooth emergence  after general 
anesthesia 
 
10)  The efficacy of intracuff lignocaine and iv lignocaine in prevention of 
emergence  phenonmenon :comparative study in neurosurgical patients   
Journal of neurosurgery anesthesiology 2006 
 
Venkatesan et al performed  in 82 patients undergoing neurosurgical 
procedures 41 patients in each group. 
Group 1 received intracuff lignocaine 4% 
Group 2 received lignocaine 1.5%iv before extubation  
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After extubation ,vital parameter recorded every 1 minute for 5 minutes and 
compared with baseline parameters. From the study he concluded that both 
the drugs produce similar effects in decreasing cough after extubation 
 
11) Intra cuff, topical, intravenous lignocaine – comparative study- for 
prevention of coughing during emergence in general anesthesia . 
 
    Zamora et al conducted a study in patients with an ASA physical 
status of I or II over 18 years of age scheduled for elective surgery lasting 
between 60 and 120 minutes under balanced anesthesia with orotracheal 
intubation. These patients were randomly allocated to one of 3 groups 
(intravenous lignocaine, topical lignocaine, or intra cuff lignocaine) or to 
the control group.  
Percentage of coughing in three groups: 
Control group: 65% presented coughing  
Topical lignocaine group: 26.3% 
Intra cuff group: 15.8%   
Intravenous group: 16%  
Intravenous lignocaine and intra cuff lignocaine significantly reduce the 
incidence of coughing during emergence from anesthesia. 
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12) ETT cuff filled with Lignocaine 10%: Serum lignocaine 
concentrations,Hemodynamic changes and effects on organ systems. 
European journal of anesthesiology 2000 
 
Altintas et al conducted a study by instilling 10% lignocaine in endotracheal 
tube Cuff. Serum concentrations of lignocaine were studied. 70 ASA Class I 
or II patients who underwent plastic surgery were allocated into two groups: 
group L: ETT  inflated with  lignocaine 10% 
group S:ETT inflated with saline   
The peak  cuff pressure and hemodynamic changes were less in group 
L than group S.Group L had decreased severity and incidence of sore throat. 
Plasma concentration of lignocaine did not go upto toxic levels at the end of 
extubation. Lignocaine was better in reduction of  postoperative sore throat 
both in severity and incidence. 
 
13) Endotracheal tube cuffs inflated with lignocaine – a mode of drug 
administration: a study both in Vivo and In vitro.  
Gilles dollo .Anesthesiology – European Journal  2001 
 
Gilles dollo et al done a in vitro study regarding the release of 
lignocaine in three different forms (base form, hydrochloride form, 
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alkalinised form).From this study he concluded that alkalinised form of 
lidocaine requirement is less compared to other two forms. Endotracheal 
tube tolerance air < hydrochloride form alkalinised form (decreased pain 
score) in this order.   
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MATERIALS AND METHODS  
Study Type: Interventional 
 
Study design: 
Prospective, randomized, double blinded study. 
 
Study population: 
After getting ethical committee approval and informed consent 50 
patients of both sexes(male/female) who underwent breast & abdominal 
surgeries by general anaesthesia using Nitrous oxide at GOVT. RAJAJI 
HOSPITAL, MADURAI, were taken up for study. 
 
Groups  
          GROUP A:  Inflated with air upto  pressure of 20 cm of water.  
GROUP  L:  Inflated with alkalinized lignocaine(2% lignocaine : sodium  
bicarbonate 19:1 up to pressure of 20 cm of water. 
 
Inclusion Criteria: 
 ASA physical status class I ,II and III 
 Age between 18 and 65 years  
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Exclusion Criteria: Patients with  
History of known allergic to local anaesthetics, 
 Tracheostomy, 
 Laryngeal disease/surgery,  
 H/O smoking,  
 Those requiring insertion of nasogastric tube,  
 Those requiring more than 1 attempt to achieve tracheal intubation . 
 
Probability sampling: 
50 lots were randomized (25 in each group) from the people who were 
willing to take part in the study. All the patients stand an equal chance of getting 
into any group. All the patients were aware of the study and informed consent 
was obtained. 
 
Materials: 
1. Endotracheal tube (made of polyvinyl chloride single use) 
2. Cuff pressure monitor, cuff syringe 
3. 2% lignocaine (without adrenaline) 30 ml vial 
4. 7.4% sodium bicarbonate, 
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Monitors used: 
 
          1. Pulse oximeter (PR,SPO2) 
          2. Non-invasive blood pressure monitor.(NIBP) 
          3. End-tidal carbon dioxide.(ETCO2) 
          4. Cuff pressure monitor. 
 
Methodology: 
In the preoperative waiting room detailed history and physical 
examination was done. Basic investigations were collected. Baselines data like 
pulse rate, blood pressure, SPO2. Group A &Group L were explained about the 
procedures and postoperative follow up pattern.  The VAS was explained as 0-
10 cm scale reading and patient was asked to tell the number. 
All Patients were pre medicated with Inj. Glycopyrolate 0.2 mg intramuscularly  
45 minutes before surgery. Monitors were connected. Intravenous cannula  
secured and connected to i. v fluids. Patient were  preoxygenated with 100%  
O2 for 3 minutes. Patient is induced with Inj. fentanyl 2 micrograms/kg ,Inj. 
propofol 2mg/Kg i.v, Inj. Atracurium 0.5 mg/kg and intubated with 7.5 
mm(females), 8.5mm(males) endotracheal tube. 
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GROUP A:Inflated  with air upto pressure of 20 cm of water.  
GROUP L: Inflated with alkalinized  lignocaine(2% lignocaine : sodium bi  
carbonate 19:1 up to pressure of 20 cm of water. 
Bilateral air entry checked and connected to closed circuit. Patient is maintained 
with N2O : O2 2:2, Inj.fentanyl 1 micrograms/kg every 45 mins, inj. atracurium 
in  titrated  doses. Baseline cuff pressure before N2O administration is 
monitored. Cuff pressure is recorded every 30 minutes thereafter .At the end of 
surgery, cuff pressure, tube tolerance, volume of air/alkalinized lignocaine 
deflated during extubation were noted. After adequate attempts  of respirations, 
patient is reversed with inj.Glycopyrolate 10 mics/kg, inj. neostigmine 40 
mics/kg and  extubated after deflation of the cuff. 
 
INTRAOPERATIVELY following parameters were monitored. 
1. PR,BP,SPO,.ETCO2,Cuff pressure was noted before nitrous oxide  
 administration ,&every 30 minutes till the end of surgery. 
2. Tube tolerance ,BP, PR, volume of air /lignocaine deflated were noted. 
POSTOPERATIVELY following parameters were noted: 
Coughing,sorethroat,hoarseness were  monitored 30 minutes after surgery in  
postanaesthesia care unit & 24 hours later. 
Pain was assessed using visual analogue scale. 
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DATA ANALYSIS 
PROFILE OF CASES STUDIED 
Group A:  Endotracheal tube filled with air 
Group L:  Alkalinised Lignocaine 
Statistical Tools ( To be included at the end of Materials and Methods) 
The information collected regarding all the selected cases were recorded 
in a Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2010) developed by Centre for 
Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, standard 
deviations, chi square and  'p'  values were calculated. Kruskul Wallis chi-square  
test was used to test the significance of difference between quantitative 
variables and Yate’s chi square test for qualitative variables. A 'p' value less 
than 0.05 is taken to denote significant relationship 
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OBSERVATION AND RESULTS 
Table 1: Age distribution 
Age group 
Group A Group L 
No % No % 
20-29 years 8 32 - - 
30-39 years 2 8 5 20 
40-49 years 9 36 8 32 
50 years & above 6 24 12 48 
Total 25 100 25 100 
Range 20-60 23-60 
Mean 39.7 40.3 
SD 12.8 10.5 
‘p’ 0.8765  Not significant 
 
With respect to age, both groups were comparable 
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Table 2: Sex distribution 
Sex 
Group A Group L 
No % No % 
Male 12 48 9 36 
Female 13 52 16 64 
‘p’ 0.5666 Not significant 
 
 
                Sex distribution shows no statistical significant difference. 
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Table 3: ASA 
 
ASA 
Group A Group L 
No % No % 
I 12 48 6 24 
II 10 40 19 76 
III 3 12 - - 
Total 25 100 25 100 
 
 
                 ASA risk is comparable in both groups.  
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Table 4: Changes in Systolic Blood pressure 
 
SBP at 
SBP ( mm/Hg)in 
 
‘p’ 
 
Significance 
Group A Group B 
Mean SD Mean SD 
Before N2O 132 10.4 124.7 12.5 0.0783 Not significant 
30 minutes 124.4 11.3 127.6 11.7 0.2982 Not significant 
60 minutes 126.7 12.2 125.0 10.2 0.9922 Not significant 
90 minutes 126.8 12.0 125.5 5.7 0.381 Not significant 
120 minutes 125.4 10.1 124.9 5.4 0.559 Not significant 
End of surgery 128.9 10.2 123.8 6.8 0.1724 Not significant 
 
             Systolic Blood pressure shows no statistical significant difference. 
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Table 5: Changes in Diastolic Blood pressure 
 
DBP at 
Diastolic B.P( mm/Hg) in 
 
‘p’ 
 
Significance 
Group A Group L 
Mean SD Mean SD 
Before N2O 84.8 8.9 86.1 9.3 0.5121 Not significant 
30 minutes 84.3 7.0 86.7 8.6 0.3999 Not significant 
60 minutes 83.0 10.8 86.8 10.5 0.2319 Not significant 
90 minutes 85.2 6.8 83.2 8.7 0.5984 Not significant 
120 minutes 85.9 8.9 83.4 6.4 0.5392 Not significant 
End of surgery 87.6 8.3 84.8 5.3 0.1058 Not significant 
 
Diastolic Blood pressure showed no statistical significant difference between 
two groups. 
 
 
 
 
 
 
 
 
 
  
CHANGES IN DIASTOLIC B.P. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
84.8 84.3
83
85.2 85.9
87.6
86.1 86.7 86.8
83.2 83.4
84.8
60
65
70
75
80
85
90
95
100
Before
N2O
30
minutes
60
minutes
90
minutes
120
minutes
End of
Surgery
M
ea
n 
D
B
P
GROUP A GROUP L
 55 
 
Table 6: Changes in pulse rate 
Pulse rate at 
Group A Group L 
‘p’ Significance 
Mean SD Mean SD 
Before N2O 100.2 15.1 95.2 9.0 0.2805 Not significant 
30 minutes* 97.4 9.6 94.2 7.2 0.156 Not significant 
60 minutes 83.0 10.8 86.8 10.5 0.2319  Not significant 
90 minutes 85.2 6.8 83.2 8.7 0.5984 Not significant 
120 minutes 85.9 8.9 83.4 6.4 0.5392 Not significant 
End of surgery 86.4 5.1 84.4 5.6 0.3142 Not significant 
 
Pulse rate showed no statistical significant difference between two groups. 
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Table 7: Changes in ETCO2 
ETCO2 at 
ETCO2 in 
‘p’ Significance Group A Group L 
Mean SD Mean SD 
Before N2O 31.1 3.1 32.5 2.9 0.1344 Not significant 
30 minutes 31.8 3.1 32.6 3.1 0.4393 Not significant 
60 minutes 32.0 3.2 31.7 3.3 0.8906 Not significant 
90 minutes 31.2 2.8 32.8 2.9 0.1081 Not significant 
120 minutes 31.7 3.0 31.7 3.0 0.9142 Not significant 
End of surgery 32.6 3.7 31.6 2.8 0.4704 Not significant 
  
             Regarding ETCO2 p value is insignificant 
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Table 8: Changes in SPO2 
SPO2 
SPO2 in 
‘p’ Significance Group A Group L 
Mean SD Mean SD 
Before N2O 99.4 0.9 99.5 0.5 0.9824 Not significant 
30 minutes 99.4 0.8 99.3 0.7 0.4361 Not significant 
60 minutes 99.2 0.7 99.3 0.7 0.5059 Not significant 
90 minutes 99.3 0.7 99.3 0.7 0.7664 Not significant 
120 minutes 99.2 0.7 98.8 0.6 0.1021 Not significant 
End of surgery 99.0 1.1 99.0 0.5 0.2844 Not significant 
 
            SPO2 shows no significant difference between two groups.  
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Table 9: Changes in cuff pressure 
Cuff pressure at 
Cuff pressure in 
‘p’ Significance Group A Group L 
Mean SD Mean SD 
Before N2O 20 - 20 - - - 
30 minutes 22.7 1.7 20.3 0.5 0.0001 Significant 
60 minutes 25.4 2.3 20.7 0.8 0.0001 Significant 
90 minutes 27.6 2.1 19.9 0.7 0.0001 Significant 
120 minutes 29.7 2.2 19.1 0.7 0.0001 Significant 
End of surgery 31.5 1.8 18.8 0.7 0.0001 Significant 
 
P value is < 0.0005 which shows there is a statistical difference between the two  
Groups  regarding cuff pressure. 
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Table 10: Duration of Anaesthesia 
Group 
Duration of Anaesthesia ( in minutes) 
Range Mean SD 
Group A 120-180 135.5 16.2 
Group L 120-165 135.6 12.9 
‘p’ 0.755 (not significant) 
 
         Duration of anaesthesia is comparable between two groups. 
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Table 11: Endotracheal tube tolerance at time of extubation 
ET tube tolerance at 
time of extubation 
Group A Group L 
No % No % 
Yes 15 60 7 28 
No 10 40 18 72 
‘p’ 0.0461 (significant) 
 
Endotracheal tube tolerance was better in group L in comparision to group A. 
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Table 12: Vital parameters at the time of extubation 
At the time of 
extubation 
Group A Group L 
‘p’ 
No % No % 
Pulse rate 117.5 7.2 105.9 12.3 0.0003  
Significant 
SBP ( mm/Hg) 149.0 7.5 130.6 10.5 0.0001  
Significant 
DBP ( mm/Hg) 95.1 6.6 91.4 9.1 0.1795  
Not significant 
 
Pulse rate, systolic blood pressure shows significant difference at the time of  
extubation whereas diastolic blood pressure is similar in both groups. 
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TABLE 13: CUFF VOLUME 
   
‘p’ 
 
Significance Group A Group L 
Mean SD Mean SD 
Volume 
inflated.(ml) 
9.56 2.26 9.4 1.94 0.833 Not significant
Duration of 
anaesthesia (min.) 
135.5 16.2 135.6 12.9 0.755 Not significant
Volume deflated 
(ml). 
12.34 2.26 8.5 1.94 0.0001 Significant 
 
Volume of the cuff contents deflated at the time of extubation shows  
Statistical significant difference between Group A and Group L. 
 
 
 
 
 
 
 
 
 
 
CUFF VOLUME 
 
 
 
 
 
 
 
 
 
 
 
 
 63 
 
Table 14: Sore throat 
Sore 
throat at 
No. of cases in 
‘p’ Group A Group L 
Yes No Yes No 
No % No % No % No % 
30 minutes 5 20 20 80 2 8 23 92 0.2087  
(Not significant) 
24 hours 10 40 15 60 2 8 23 92 0.0204 
Significant 
 
 After 24 hours of extubation, occurrence of sore throat was less in group L. 
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Table 15: Coughing 
Coughing at 
Group A Group B ‘p’ 
Yes No Yes No 
No % No % No % No % 
30 minutes 6 24 19 76 4 16 21 84 0.7237  
Not significant 
24 hours - - 25 100 - - 25 100 - 
 
      Incidence of coughing is similar in both groups. 
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Table 16: Hoarseness 
Hoarseness 
at 
Hoarseness in 
‘p’ 
Group A Group L 
Yes No Yes No 
No % No % No % No % 
30 minutes 10 40 15 60 4 16 21 84 0.1153  
Not significant 
24 hours 12 48 13 52 5 20 20 80 0.0733  
Not significant 
 
Hoarseness is similar in both groups. 
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DISCUSSION: 
Nitrous Oxide is normally used in patients  undergoing  general 
anaesthesia with controlled  ventilation. During anaesthesia, nitrous oxide 
diffuses more rapidly into air filled cuff  which depends on partial pressure 
across PVC cuff membrane. When cuff pressure exceeds the tracheal mucosal 
capillary pressure(>30mmHg),tracheal erosion occurs which causes cough 
&sore throat postoperatively. 
 
Activation of rapidly acting stretch receptors in trachea will stimulate  
cough so that smooth extubation is not possible which will increase the systemic 
vascular resistance & agitation. 
 
V.V.Ravichandran et al demonstrated that instillation of alkalinized 
lignocaine into the cuff reduces these complication. Use of buffered lignocaine 
increases the diffusion of local anesthetics  & also decreased the amount of 
lignocaine used. Absorption of lignocaine into systemic circulation is very less. 
Since tracheal mucosal epithelium is very thick ,absorption rate is very low with 
prolonged local action. 
Navvaro et al demonstrated in his study in which addition of 1ml of 
sodium bicarbonate (7.4%) to 19ml of lignocaine hydrochloride changes the 
acidic pH(6.92) to alkaline pH (7.43),similar dilution is used in my study. 
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Sconzo et al reported that endotracheal tube cuff filled with lignocaine 
diffuses across the PVC membrane & quantity of diffusion depends on the 
concentration of lignocaine and the duration of contact with tracheal mucosa. 
These can be done for the patient in ventilatory support for prolonged period as 
proven by previous study. Requirement of narcotics is less for the patient   
recieving buffered lignocaine. 
 
COMPARISION OF RESULTS: 
In this study GROUP A(ROOM AIR) & GROUP L (ALKALINIZE 
LIGNOCAINE) patients were comparable with age, sex, ASA risk, duration of 
surgery which is similar to the study done by Navvaro et al & Estebe et al. In 
my study there is a no significant changes intraoperative  systolic blood pressure 
pulse rate, diastolic pressure  between two groups. This was similar to the study 
done by Navvaro et al. 
In contrast, Huang et al reported less incidence of hemodynamic changes 
intraoperatively compared to saline group in which there is an increase in 
systolic mean arterial pressure compared to other.  
Pressure exerted by pilot balloon is the indirect measure of the pressure 
exerted by the cuff on the tracheal mucosa In regards to cuff pressure, in my 
study there is a significant increase in cuff pressure in Group A compared to 
Group L(p=0.0001) in which there is a decrease in cuff pressure after 90 
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minutes of anaesthesia  similar to study done by Navvaro et al. He  
demonstrated the significant rise in cuff pressure in air group after 30 minutes 
of anaesthesia compared to lignocaine group he studied.They have done an 
another study in which they have compared with saline instead of air. Saline 
group shows significant rise in cuff pressure compared to lignocaine group in 
which cuff  pressure remains constant. 
 
Volume of air/lignocaine removed after extubation shows significant 
difference in my study .Though I have injected approximately 9.5ml of air/ 
lignocaine after intubation, volume of air &lignocaine deflated during 
extubation was 12ml & 8.5ml respectively(p=0.0001).This was similar to study 
done by Navvaro et al who injected 5 & 6.5 ml of air & lignocaine respectively. 
The mean volume of air & lignocaine removed was 8 & 5 ml respectively.  
 
Shroff et al found out that volume of air deflated is more related to volume 
of air inflated as compared to decrease in volume of buffered lignocaine .This 
increase in volume of air denotes that Nitrous oxide diffuses through the air 
filled cavities which doesn’t occur with fluid filled cavities. Decrease in the 
volume of alkalinized lignocaine denotes the permeability of buffered 
lignocaine to polyvinyl chloride endotracheal tube wall. Diffusion of lignocaine 
anaesthetize the tracheal mucosa thereby reducing the airway irritation.  
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 Hirota et al studied that tracheostomy cuff filled with lignocaine reduces 
airway discomfort by 50%. In my study incidence of agitation during extubation 
was lower in Group L compared to Group A(p=0.0461). 
This result was similar to the study done by V.V.Ravichandran et el who 
demonstrated smooth extubation in patients with hyper-reactive airway 
receiving intra cuff buffered lignocaine compared to air& normal saline.  
Similarly Navvaro et al also demonstrated that incidence of agitation 
during extubation was lower in buffered lignocaine group compared to air 
group. 
Behzadi et al reported the efficiency of intra cuff lignocaine by promoting 
smooth emergence in children undergoing adenotonsillectomy compared to 
saline group. In my study there is a maintanence of systolic blood pressure & 
pulse rate in Group L compared to Group A in which there is a significant 
increase in above parameters at the time of extubation. 
  
But the study done by Navvaro et al shows rise in systolic blood pressure 
at time of extubation both in air & lignocaine group(air >lignocaine) .The 
diastolic pressure and the heart rate doesnot Change. 
    Estebe et al found out that there was no significant difference in heart rate 
& blood pressure at time of extubation in both air & lignocaine group. 
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Behzadi et al reported the efficiency of intra cuff lignocaine by promoting 
smooth emergence in children undergoing adenotonsillectomy compared to 
saline group. In my study there is a maintanence of systolic blood pressure & 
pulse rate in Group L compared to Group A in which there is a significant 
increase in above parameters at the time of extubation.  
 
          But the study done by Navvaro et al shows rise in systolic blood pressure 
at time of extubation both in air &lignocaine group(air >lignocaine) .The 
diastolic pressure and the heart rate doesnot Change. 
 
     Estebe et al found out that there was no significant difference in heart rate 
& blood pressure at time of extubation in both air & lignocaine 
group.Parameters at the time of extubation when intra cuff saline or lignocaine 
is  injected. 
 
Venkatesan et al showed that there was no significant difference in 
haemodynamic parameters between I.V. lignocaine and intra cuff 4% lignocaine 
at the extubation when he conducted study in neurosurgical patients. Altintas et 
al found out that endotracheal tube cuff filled with 10% lignocaine produces 
less hemodynamic responds during extubation compared to intra cuff saline 
groups.  
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Huang et al concluded that hemodynamic changes in systolic pressure 
was higher in 4% lignocaine group compared to buffered lignocaine (4% 
lignocaine + 1ml of sodium bicarbonate). This result was similar to my result. 
Regarding sore throat in my study there was no significant difference between 
air (group A) and lignocaine group(L) after 30 minutes of extubation. But after  
24hours of extubation incidence of sore throat was significantly lower in group 
L compared to group A.  
 
          This was similar to study done by Navvaro et al who demonstrated that 
incidence of sore throat was lower in incidence after 24 hours of extubation 
when he compared intra cuff air and lignocaine.  
 
There was no notable difference between two groups immediately after 
extubation. V.V.Jaichandran et al concluded in his study that the incidence of 
sore throat was lower to in lignocaine group compared to air group.  
 
Lecorre et al recorded that incidence of sore throat was lower in buffered 
lignocaine group compared to air group during the postoperative period. 
 Soltani et al concluded in his study, by comparing intra cuff alkanized 
lignocaine and intra venous lignocaine at the end of surgery decreases the 
incidence of sore throat in both groups. 
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Huang et al observed from his study that there is a 35% of decrease in 
incidence of sore throat in buffered lignocaine group compared to normal saline 
group. 
 
Above study results were similar to my results but according to Porter et 
al who observed that there was no significant difference in sore throat by 
comparing intra cuff lignocaine, saline and air group. 
 
 Rapidly adapting stretch receptors present over the tracheal mucosa are 
stimulated by endotracheal tube intubation and hyperinflation of the cuff during 
general anaesthesia using nitrous oxide which was responsible for the cough 
after extubation. Anesthetizing the tracheal mucosa with lignocaine prevents 
this complication during immediate and late postoperative period. 
 
The incidence of coughing in postoperative period does not produce any 
significant difference in my study this was similar to the study done by Navvaro 
et al.  
 
Soltani et al demonstrated that intra cuff lignocaine decreases the 
incidence of postoperative cough compared to other groups (different 
application of lignocaine). 
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Sagheer et al compared intra cuff 4% lignocaine and air group and found 
out that there was decrease in the frequency of coughing at extubation and 
postoperative period lignocaine group compared to other.  
 
According to Fagan et al incidence of coughing was lower in lignocaine 
group in the initial post extubation period when compared to saline or 
lignocaine group.  
 
Above studies showed that incidence of cough was lower in lignocaine 
group but in my study there was no significant reduction in cough between two 
groups I compared. 
 
 
Incidence of hoarseness was low but does not produce any significant 
difference between air and lignocaine group in my study. This was similar to 
study done by navvaro et al.  
 
Le corre et al reported less incidence of hoarseness in intra cuff buffered 
lignocaine group compared to intra cuff air group. 
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Shroff et al observed in his study that there was decrease in incidence of 
hoarseness in intra cuff lignocaine group compared to intra cuff air group. 
Shin et al concluded in his study that the use of intra cuff alkanized lignocaine 
decrease the incidence of hoarseness compared to intra cuff air group. 
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SUMMARY OF THE STUDY: 
 This study was carried out at Govt. Rajaji hospital, Madurai in 50 
patients of age 18-65 years of ASA I,II,&III who underwent abdominal &breast 
surgeries under general anaesthesia with N2O.They were divided into two 
groups 25 patients in each group.  
GROUP A:Inflated with air upto pressure of 20 cm of water. 
GROUP L: Inflated with alkalinized lignocaine(2% lignocaine : sodium 
bicarbonate 19:1 up to pressure of 20 cm of water . 
All Patients were pre medicated with Inj. Glycopyrolate 0.2 mg intramuscularly 
45 minutes before surgery. Monitors were connected. Intravenous cannula 
secured and connected to i. v fluids. Patient were pre oxygenated with 100% O2 
for 3 minutes. Patient is induced with Inj. fentanyl 2 micrograms/kg ,Inj. 
propofol 2mg/Kg i.v, Inj. Atracurium 0.5 mg/kg and intubated with 7.5 
mm(females), 8mm(males) endotracheal tube. Endotracheal tube was inflated 
according to study group. 
 
 Bilateral air entry checked and connected to closed circuit. Patient is 
maintained with N2O : O2 2:2, Inj. fentanyl 1 micrograms/kg, inj. atracurium in  
titrated  doses Baseline cuff pressure before N2O administration is monitored. 
Cuff pressure is recorded every 30 minutes thereafter .At the end of surgery, 
cuff pressure, tube tolerance, volume of air/alkalinized lignocaine deflated 
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during extubation were noted. After adequate attempts of respirations, patient is 
reversed with inj.Glycopyrolate 10 mics/kg , inj. neostigmine 40 mics/kg and  
extubated after deflation of the cuff. 
 
INTRAOPERATIVELY following parameters were monitored. 
 1. PR, BP, SPO, ETCO2, Cuff pressure were noted before nitrous oxide  
administration ,&every 30 minutes till the end of surgery. 
 2. Tube tolerance ,BP, PR, volume of air /lignocaine deflated were noted. 
 
 POSTOPERATIVELY following parameters were noted: Coughing, sore 
throat, hoarseness were monitored 30 minutes after surgery in post 
anaesthesia care unit & 24 hours later. Pain was assessed using visual 
analogue scale. 
 
 This study showed that 
1.  Intracuff injection of alkalinized lignocaine reduces the cuff pressure during 
general anaesthesia with N2O compared to cuff inflated with air in which 
there is a gradual increase in cuff pressure. 
2.  Incidence of rise in systolic blood pressure during extubation was more in 
GROUP A compared to GROUP L. 
3.  ET tube tolerance during extubation was more with GROUP L compared to  
 77 
 
GROUP A. 
4.  Volume of lignocaine deflated during extubation was less than the infleated 
volume. But volume of air deflated was more than the inflated volume. 
5.  Incidence of sore throat was similar in immediate & less in late 
postoperative period in intra cuff lignocaine group (GROUP L) compared to  
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CONCLUSION: 
From the data &statistical analysis, intracuff injection of alkalinized 
lignocaine instead of room air reduces the cuff pressure which provide better 
endotracheal tube tolerance with less hemodynamic changes during extubation 
& less incidence of sorethroat in post operative period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 79 
 
BIBLIOGRAPHY: 
1. Miller’s anesthesiology  seventh edition, Morgan’s clinical           
anesthesiology fourth edition 
2. Ellis’anatomy  eighth edition. 
3. Text book of pharmacology-K.D .Tripathi   sixth edition. 
4.  Goodman & Gillman text book of pharmacology. 
5. Dorsch & Dorsch’s understanding anaesthesia equipment  fifth edition. 
6. Navarro RM, Baughman VL. Lidocaine in the endotracheal tube  cuff  
      reduces postoperative sore throat. J Clin Anesth.1997;9(5):394-7. 
7. Huang CJ, Hsu YW, Chen CC, et al. Prevention of coughing induced by   
      endotracheal tube during emergence from general anaesthesia--a  
comparison  between three different regimens of lidocaine fi lled in the 
endotracheal tube    cuff. Acta Anaesthesia scandinacica. 1998;36(2):81-6. 
8. Fagan C, Frizelle HP, Laffey J, Hannon V, Carey M. The effects of 
intracuff  lidocaine on endotracheal-tube-induced emergence phenomenon 
after general anaesthesia. Anesth Analg.2000;91(1):201-5. 
9. Altintas F, Bozkurt P, Kaya G, Akkan G. Lidocaine 10% in the 
endotracheal tube cuff: blood concentrations, haemodynamic and clinical 
effects. Eur J Anaesthesiology. 2000;17(7):436-42. 
10. Dollo G, Estebe JP, Le Corre P, Chevanne F, Ecoffey C, Le Verge R.  
       Endotracheal tube cuffs fi lled with lidocaine as a drug delivery system:  
 80 
 
      invitro and in vivo investigations. Eur J Pharm Sci. 2001;13(3):319-23. 
11. Estebe JP, Dollo G, Le Corre P, et al. Alkalinization of intracuff lignocaine 
improves endotracheal tube-induced emergence phenomenon. Anesth 
Analg. 2002;94(1):227-30. 
12. Soltani HA, Aghadavoudi O. The effect of different lignocaine 
            application methods on postoperative cough and sore throat. J 
           Clin Anesth. 2002;14(1):15-8. 
13. V.V.Ravichandran,V.Jegadeesh,et al.Intracuff buffered lignocaine versus  
          saline or air  SAJAA  2009  15(2) :11-14. 
14. Le Corre P,Dollo G, Chevanne F, Ecoffey C.Alkalinization of intracuff  
          lignocaine : efficacy & safety. Journal of  anaesthesia analgesia 2005. 
15. Shroff PP, Patil  V.Efficacy of cuff inflation media to prevent post   
intubation-related emergence phenomenon:air,saline& alkalinised 
lignocaine. 
16. Shin JC, Kim KS, Kim YJ,Choi WJ, Koo MS.The effects of the 
alkalinization of intracuff lignocaine after Nitrous Oxide Anaesthesia. 
Korean    journal of anesthesiology 2008. 
17. Venkatesan T,Korula G.A comparative study between the effects of 4%  
endotracheal tube cuff lignocaine & 1.5mg/Kg  I.V.lignocaine on coughing 
&  haemodynamics during extubation in neurosurgical patients. Journal of 
neurosurgery anesthesiology 2006./ 
 81 
 
STUDY PROFORMA: 
COMPARATIVE STUDY OF THE CUFF PRESSURE BETWEEN AIR  
AND ALKALINISED LIGNOCAINE IN GENERAL ANAESTHESIA. 
 
NAME:                               AGE:                       SEX:                  I.P.NO: 
  
 
ASA:                                  MPG:                      DIAGNOSIS: 
 
 
PROCEDURE:                                                 DURATION OF SURG: 
 
LAB.TEST: 
                 Hb%,  
                BLOOD SUGAR ,UREA ,CREATININE ., 
               S.ELECTROLYTES, 
               ECG ,CHEST X-RAY (P.A. VIEW) 
 
STUDY GROUP:   
                             GROUP A- ROOM AIR 
                            GROUP L-ALKALINISED LINOCAINE 
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INTRA OP:                     
                                                        (TIME IN MINS) 
                  BEFN20 
ADMIN     
      
     30        
         
       60      
    
       90      
     
      120     
END OF  
SURG        
PR       
BP       
SPO2       
PCO2       
CUFF PR       
                                    
DURATION OF ANAESTHESIA: 
TIME OF EXTUBATION: 
                  1.presence of agitation dur.spont ven(yes/no)- 
                  2.PR-             BP- 
                 3.vol.of air/lignocaine on deflation: 
PACU:                                                             
                                                 30 MINS                             24 HRS (VAS) 
COUGHING   
SORE THROAT   
HOARSENESS   
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130 85 85 35 99 25 115 83 90 33 99 27 130 74 90 29 99 30 YES 115 150 100 11 NO NO NO YES YES YES
114 84 89 35 99 29 130 82 95 34 99 31 150 108 85 33 100 33 NO 120 140 100 10 YES NO NO NO NO NO
123 80 84 33 99 25 120 79 89 30 99 28 122 80 90 30 99 30 YES 108 155 90 13 NO NO NO YES NO YES
114 90 100 28 99 28 123 95 94 28 98 30 129 89 84 35 98 32 YES 122 154 89 15 NO NO YES NO NO YES
125 85 98 29 100 27 130 85 94 25 98 29 122 85 96 32 96 32 YES 125 160 100 14 NO NO NO NO NO NO
100 90 85 26 100 26 110 75 88 29 100 28 125 85 90 30 98 30 YES 114 142 92 10 YES NO NO YES YES YES
138 98 99 33 100 28 130 100 94 32 99 30 120 92 99 28 99 33 NO 110 150 100 9.5 NO NO NO NO NO YES
132 85 96 29 100 31 129 92 99 33 99 33 130 90 82 39 98 33 YES 128 155 95 10 YES NO NO YES YES YES
133 88 90 33 100 27 132 99 95 35 100 29 126 85 94 35 99 32 YES 130 160 100 11 YES NO YES YES YES YES
144 85 100 35 100 25 128 95 96 33 100 27 140 90 95 38 99 29 NO 112 140 90 10 NO NO NO NO NO NO
143 102 108 30 98 29 132 100 102 28 100 32 132 98 86 39 100 33 YES 122 135 90 15 NO NO NO NO YES YES
126 94 103 32 98 25 140 95 96 30 100 27 130 90 92 33 100 29 NO 110 144 86 10 NO NO NO NO NO NO
105 75 87 29 98 30 125 85 92 32 100 32 142 90 84 32 100 33 YES 108 154 96 16 NO NO YES NO NO YES
120 84 78 28 98 31 110 85 85 29 100 33 112 75 89 30 100 33 NO 110 145 85 15 NO NO NO YES YES NO
125 85 85 26 100 25 144 76 95 33 100 27 128 90 86 29 100 29 YES 128 158 95 11 YES NO NO YES NO NO
144 79 99 33 100 27 134 85 90 35 100 30 132 78 95 26 99 32 NO 122 143 93 15 NO NO NO NO NO YES
110 86 93 34 100 29 120 76 88 37 100 32 110 90 93 29 99 33 YES 118 145 98 14 NO NO NO NO NO NO
133 76 95 30 100 26 109 79 100 29 100 29 150 98 88 36 98 31 YES 122 158 110 11 NO NO YES NO YES NO
118 90 87 31 100 25 142 102 95 30 100 25 123 74 82 38 97 27 NO 112 142 85 11.5 NO NO NO NO NO NO
123 73 90 28 99 30 125 76 79 33 100 32 122 76 89 36 98 33 NO 110 139 90 15 NO NO NO YES YES NO
140 79 112 33 99 28 110 88 103 35 99 30 140 90 80 33 100 32 YES 128 160 100 10 YES NO YES NO NO NO
132 82 93 29 99 30 133 76 100 37 99 32 118 98 84 30 100 33 NO 114 145 90 11 NO NO NO YES YES NO
140 90 100 32 99 26 120 80 86 28 99 28 122 85 82 29 100 30 NO 111 149 108 10.5 NO NO NO NO NO YES
130 85 89 35 99 30 115 75 80 32 99 32 129 89 89 31 100 33 YES 125 155 100 15 NO NO NO YES YES NO
127 80 93 33 99 27 130 85 99 33 99 30 138 90 85 34 100 33 YES 114 148 95 15 NO NO NO NO NO YES
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1 ligno Baskaran 23 M 4045 I I 130 11 120 90 112 32 99 20 110 98 95 33 99 20 109 85 95 33 99 20
2 ligno  Sundar 32 M 9953 I I 120 12 140 100 95 35 99 20 124 78 92 35 99 21 121 89 92 36 99 21
3 ligno Kannan 42 M 9224 I 135 12 126 80 84 37 99 20 114 78 86 33 99 20 119 85 86 32 99 21
4 ligno Kamatchi 25 M 63444 II I 128 12 110 79 95 30 99 20 143 89 90 31 98 20 133 76 90 30 99 20
5 ligno Ayyammal 50 F 69648 I I 140 8 130 90 100 32 99 20 125 90 88 29 98 20 132 92 88 29 98 21
6 ligno Ganesan 43 M 73490 II I 160 13 122 95 88 29 99 20 143 90 111 28 98 21 140 90 111 33 98 22
7 ligno Arockiammal 52 F 73447 II I 150 8 135 90 92 27 100 20 133 90 99 30 98 20 129 100 99 31 98 21
8 ligno Mariam 30 F 80948 I I 120 8 140 100 111 31 100 20 132 77 97 31 100 20 130 100 97 33 98 20
9 ligno Mayathevar 50 M 83449 II I 133 12 128 100 108 35 100 20 142 89 100 35 100 20 136 76 100 36 99 21
10 ligno Neela 60 F 2180 II I 160 8 125 85 102 38 100 20 120 80 86 32 100 21 125 75 86 33 100 22
11 ligno Lakshmi 51 F 83730 II I 130 8 100 70 86 39 100 20 122 98 98 30 100 20 106 86 98 29 100 21
12 ligno Indira 42 F 3900 II I 145 8 115 85 92 33 100 20 142 96 103 33 100 20 132 84 103 25 100 21
13 ligno Prema 41 F 4121 II I 140 8 120 90 85 32 100 20 125 78 89 39 100 20 116 83 89 30 100 20
14 ligno Nagavalli 34 F 4130 II I 135 8 112 78 90 33 100 20 127 90 95 35 100 21 120 80 95 28 100 22
15 ligno Manjula 51 F 6404 II I 165 8 132 87 100 33 100 20 142 100 109 30 100 20 129 105 109 32 100 21
16 ligno  Sundaram 31 M 9208 II I 120 11 105 70 90 35 100 20 110 80 88 31 100 20 103 63 88 33 100 20
17 ligno Rajathi 40 F 10041 II I 135 8 128 100 96 30 100 20 130 90 99 36 100 21 137 95 99 38 100 22
18 ligno Pitari 23 F 12906 II I 138 8 125 90 79 35 100 20 138 100 89 35 100 20 132 110 89 26 100 20
19 ligno Amsalakshmi 51 F 14660 II I 129 8 140 90 100 32 100 20 123 74 94 33 99 20 130 80 94 28 100 20
20 ligno Manimala 52 F 14584 I I 120 8 120 80 84 33 99 20 145 90 96 39 99 20 109 90 96 29 100 20
21 ligno Innasi 41 M 17195 II I 142 12 133 76 92 29 99 20 111 78 84 29 99 21 120 90 84 33 99 20
22 ligno Nazeema 45 F 23133 II I 125 8 140 90 94 30 99 20 129 95 92 33 99 20 127 83 92 34 99 20
23 ligno Muniammal 24 F 23099 II I 140 8 133 73 102 30 99 20 126 90 91 36 99 20 136 96 91 37 99 20
24 ligno Shanthi 40 M 23103 II I 120 12 140 90 111 33 99 20 129 75 100 32 99 21 132 79 100 33 99 22
25 ligno Suseela 34 F 22221 I I 130 8 98 75 92 30 99 20 105 75 84 28 99 20 121 79 84 31 99 20
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110 70 84 35 99 19 106 75 85 29 100 19 110 90 84 33 100 NO 108 129 100 10 NO NO NO NO NO NO
120 100 88 32 99 20 122 89 88 35 100 20 128 80 80 32 100 19 NO 98 132 85 11.5 NO NO NO NO NO NO
110 83 87 33 99 19 100 80 80 36 99 18 125 90 82 36 99 18 NO 89 120 80 11 NO NO NO NO NO NO
125 89 93 33 98 20 129 90 99 32 99 19 120 84 84 30 99 19 NO 110 136 95 11.2 NO NO NO NO NO NO
122 85 90 38 98 20 123 85 85 38 99 19 120 80 90 31 99 18 YES 122 140 100 7 YES NO NO NO YES YES
130 90 95 31 100 21 122 88 90 30 99 20 110 79 89 29 99 19 NO 109 129 98 12 NO NO NO NO NO NO
123 67 88 30 100 20 130 89 100 33 99 20 135 86 86 27 99 20 YES 125 145 110 7 NO NO NO NO NO YES
134 88 90 30 100 20 140 90 102 32 99 19 115 75 84 35 98 19 NO 100 128 87 7.5 NO NO NO NO NO NO
122 87 88 38 100 20 132 82 79 28 99 19 123 88 94 33 98 18 NO 104 125 90 11 NO NO NO NO NO NO
122 89 95 31 99 21 118 88 90 25 99 20 105 84 88 31 98 19 NO 99 110 95 6.5 NO NO NO NO NO NO
111 78 89 30 99 21 108 88 82 30 98 20 115 90 98 37 99 20 YES 128 142 100 7 YES NO YES YES YES NO
130 90 94 28 99 20 120 80 88 33 98 19 125 80 84 34 99 19 NO 109 130 75 7 NO NO NO NO NO NO
115 70 84 29 99 20 121 71 89 31 100 19 125 95 82 32 99 19 YES 127 138 98 7 YES NO NO NO NO YES
119 85 80 32 99 21 120 80 84 30 99 20 115 75 80 31 99 19 NO 88 122 80 7.5 NO NO NO NO NO NO
130 90 90 33 99 20 125 75 85 33 99 19 109 89 84 30 99 18 NO 95 111 90 6.5 NO NO NO NO YES NO
109 75 82 30 99 19 100 80 74 31 99 18 124 84 86 26 99 18 NO 92 133 94 10.5 NO NO NO NO NO NO
133 80 100 36 100 21 130 90 94 29 99 20 133 83 75 30 99 20 YES 106 149 100 7.5 NO NO NO NO NO NO
129 98 95 34 100 19 125 85 89 28 99 19 129 90 82 32 99 19 YES 119 138 99 7.2 YES NO YES YES YES NO
122 82 90 31 100 20 120 90 88 30 99 19 120 85 85 35 99 19 NO 99 110 90 7 NO NO NO NO NO NO
105 70 88 33 100 20 111 70 90 33 98 19 115 76 80 31 99 19 NO 93 123 73 7 NO NO NO NO NO NO
122 86 92 39 100 19 110 75 85 33 98 18 117 88 75 30 99 18 NO 88 129 87 11 NO NO NO NO NO NO
125 85 95 33 98 20 120 90 93 35 98 19 111 82 88 27 99 18 NO 106 142 92 7.5 NO NO NO NO NO YES
121 72 100 32 99 19 125 85 100 37 98 19 120 90 74 29 99 19 NO 102 133 88 7 NO NO NO NO NO NO
130 90 89 36 99 20 129 89 90 30 99 19 130 88 88 33 99 18 NO 111 140 100 11 NO NO NO NO NO YES
110 80 84 33 99 19 105 80 84 31 98 18 122 88 88 35 99 18 YES 120 132 80 7 NO NO NO NO NO NO
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